National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2011 (No. 13) (No. PB 95 of 2011) (Cth)
PB 95 of 2011
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2011
(No.13)1
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary (Acting), Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.
Dated 30 November 2011
FELICITY McNEILL
First Assistant Secretary (Acting)
Pharmaceutical Benefits Division
Department of Health and Ageing
1 Name of Instrument
(1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2011 (No. 13).
(2) This Instrument may also be cited as PB 95 of 2011.
2 Commencement
This instrument commences 1 December 2011, immediately following commencement of PB 83 of 2011.
3 Amendment of the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010)
Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010).
Schedule 1 Amendments
Schedule 4, Part 1, entry for Cetuximab
omit:
| Cetuximab | C2713 | Where the patient is receiving treatment in the community setting or at/from a Private Hospital Initial PBS-subsidised treatment, as monotherapy or in combination with an irinotecan based therapy, of a patient with a World Health Organisation performance status of 2 or less and with K-RAS wild type metastatic colorectal cancer after failure of first-line chemotherapy | Compliance with Authority Required procedures |
| C2714 | Where the patient is receiving treatment in the community setting or at/from a Private Hospital Continuing PBS-subsidised treatment, as monotherapy or in combination with an irinotecan based therapy, of a patient with K-RAS wild type metastatic colorectal cancer who has previously been issued with an authority prescription for cetuximab and who does not have progressive disease | Compliance with Authority Required procedures | |
| C2715 | Where the patient is receiving treatment in the community setting or at/from a Private Hospital Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx for the week prior to radiotherapy, where cisplatin is contraindicated according to the Therapeutic Goods Administration-approved Product Information | Compliance with Authority Required procedures | |
| C3843 | Where the patient is receiving treatment in the community setting or at/from a Private Hospital Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is not tolerated | Compliance with Authority Required procedures | |
| C3844 | Where the patient is receiving treatment in the community setting or at/from a Private Hospital Continuing treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is either contraindicated or not tolerated | Compliance with Authority Required procedures |
substitute:
| Cetuximab | C2713 | Where the patient is receiving treatment in the community setting or at/from a Private Hospital Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx for the week prior to radiotherapy, where cisplatin is contraindicated according to the Therapeutic Goods Administration-approved Product Information | Compliance with Authority Required procedures |
| C2714 | Where the patient is receiving treatment in the community setting or at/from a Private Hospital Initial treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is not tolerated | Compliance with Authority Required procedures |
| C2715 | Where the patient is receiving treatment in the community setting or at/from a Private Hospital Continuing treatment of stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx, in combination with radiotherapy, where cisplatin is either contraindicated or not tolerated | Compliance with Authority Required procedures |
| C3843 | Where the patient is receiving treatment in the community setting or at/from a Private Hospital Initial PBS-subsidised treatment, as monotherapy or in combination with an irinotecan based therapy, of a patient with a World Health Organisation performance status of 2 or less and with K-RAS wild type metastatic colorectal cancer after failure of first-line chemotherapy | Compliance with Authority Required procedures |
| C3844 | Where the patient is receiving treatment in the community setting or at/from a Private Hospital Continuing PBS-subsidised treatment, as monotherapy or in combination with an irinotecan based therapy, of a patient with K-RAS wild type metastatic colorectal cancer who has previously been issued with an authority prescription for cetuximab and who does not have progressive disease | Compliance with Authority Required procedures |
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See
0
0
0